1. Home
  2. SPRC vs CDT Comparison

SPRC vs CDT Comparison

Compare SPRC & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRC
  • CDT
  • Stock Information
  • Founded
  • SPRC 2004
  • CDT 2019
  • Country
  • SPRC Israel
  • CDT United States
  • Employees
  • SPRC N/A
  • CDT N/A
  • Industry
  • SPRC Biotechnology: Pharmaceutical Preparations
  • CDT Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPRC Health Care
  • CDT Health Care
  • Exchange
  • SPRC Nasdaq
  • CDT Nasdaq
  • Market Cap
  • SPRC 4.3M
  • CDT 4.2M
  • IPO Year
  • SPRC N/A
  • CDT N/A
  • Fundamental
  • Price
  • SPRC $2.78
  • CDT $2.66
  • Analyst Decision
  • SPRC
  • CDT
  • Analyst Count
  • SPRC 0
  • CDT 0
  • Target Price
  • SPRC N/A
  • CDT N/A
  • AVG Volume (30 Days)
  • SPRC 289.9K
  • CDT 125.1K
  • Earning Date
  • SPRC 01-01-0001
  • CDT 11-14-2025
  • Dividend Yield
  • SPRC N/A
  • CDT N/A
  • EPS Growth
  • SPRC N/A
  • CDT N/A
  • EPS
  • SPRC N/A
  • CDT N/A
  • Revenue
  • SPRC $1,306,000.00
  • CDT N/A
  • Revenue This Year
  • SPRC N/A
  • CDT N/A
  • Revenue Next Year
  • SPRC N/A
  • CDT N/A
  • P/E Ratio
  • SPRC N/A
  • CDT N/A
  • Revenue Growth
  • SPRC N/A
  • CDT N/A
  • 52 Week Low
  • SPRC $1.75
  • CDT $2.30
  • 52 Week High
  • SPRC $37.59
  • CDT $2,198.40
  • Technical
  • Relative Strength Index (RSI)
  • SPRC 37.96
  • CDT 53.41
  • Support Level
  • SPRC $2.51
  • CDT $2.30
  • Resistance Level
  • SPRC $3.40
  • CDT $3.22
  • Average True Range (ATR)
  • SPRC 0.22
  • CDT 0.25
  • MACD
  • SPRC -0.08
  • CDT -0.11
  • Stochastic Oscillator
  • SPRC 17.47
  • CDT 33.78

About SPRC SciSparc Ltd.

SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: